Many people with type 1 diabetes continue to have high HbA1c levels despite insulin therapy, with an associated elevated risk of cardiovascular events and increased mortality. Adjunctive prescription of a sodium–glucose cotransporter 2 (SGLT2) inhibitor in type 1 diabetes has been approved as a potential intervention. In this case series, the authors report the outcomes of six adults with type 1 diabetes who initiated on dapagliflozin in East Cheshire. Over a 6-month period, mean HbA1c fell from 78.5 mmol/mol (9.3%) to 55 mmol/mol (7.2%). Analysis of flash glucose monitoring data showed that the proportion of readings in the target range (4–10 mmol/L) increased from 33.1% to 65.2% following addition of dapagliflozin, while the proportion of readings above target (>10 mmol/L) decreased from 68.0% to 26.4%. Dapagliflozin was well tolerated and improved glycaemic control with no increase in hypoglycaemia rates.
Your web browser is out of date.
For your security and improved experience online, please update your browser.